Aligos Therapeutics, Inc. may be able to improve on the safety and efficacy for the first drug approved for non-alcoholic/metabolic dysfunction-associated steatohepatitis (NASH/MASH), Madrigal Pharmaceuticals, Inc.’s Rezdiffra (resmetirom), based on Phase IIa data for its THRβ agonist ALG-055009, but Aligos is seeking a partner to advance its drug.
Aligos also has a first-in-class Phase Ib candidate aimed at viral suppression of chronic hepatitis B that is competing for the company’s resources. CEO Lawrence Blatt told Scrip he “loves...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?